Brainomix Ltd.FinancingBrainomix Ltd. completes £14m Series C fi...University of Oxford spinout Brainomix Ltd has closed a £14m Series C round to advance its commercial expansion in the US. Funding will also support clinical uptake of its AI imaging technology in stroke … more ➔
EvonikEconomic growthUS President deprioritises biotechnologyThe U.S. administration of President Donald Trump has revoked Executive Order 14081, “Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy,” … more ➔
Adobe stock photos - DARIKAFinancingSofinnova Partners closes €165m Bioveloc...Sofinnova Partners has raised €165m within its biotech acceleration fund Biovelocita II that attracted investments fromBig Pharma including Amgen, Bristol Myers Squibb, and Pfizer Ventures. more ➔
Polish Ministry of Agriculture - MRiRWNGTPoland breaks opposition to EU NGT deregul...At the third attempt, the Polish Council Presidency has broken the resistance of the member states against the deregulation of crops produced by new genomic technologies (NGT). The new draft will enter … more ➔
SpliceBioGene therapySpliceBio lauches Phase I/II study on dual...Spanish SpliceBio has dosed the first patient with SB-007, the first dual AAV gene therapy in clinical development for Stargardt disease more ➔
FSA UKCell-based meatRegulatory sandbox will speed up safety as...The UK Food Standards Agency (FSA) has selected eight companies to participate in a two-year regulatory programme set to speed up market approval and safety assessment of cell-cultivated products. more ➔
asobe stock photos - catalin ObesityRoche inks US$1.65bn obesity deal with Zea...Roche is extending its obesity pipeline signing a US$5.3bn biobucks deal with Zealand Pharma A/S, who will co-develop and co-commercialise a monotherapy of its long-acting amylin analogue petrelintide … more ➔
Adobe stock - maurice norbert ObesityNovo Nordisk’s obesity drug CagriSem...Novo Nordisk A/S’ combined GLP1-, amylin- and calcitonin receptor agonist CagriSema has failed to meet the expected 25% weight loss within 68 weeks in the second of four pivotal Phase III trials. Shares … more ➔
Roche AGAutomationRoche unveils completely new sequencing ap...Roche researchers have introduced a greatly improved long-read nanopore sequencing method that has the potential to erase the sequencing-by-synthesis approach of market leader Illumina. more ➔
Hummingbird BioscienceFinancingADC maker Callio Therapeutics secures US$1...Investment company Frazier Life Sciences has launched the virtual ADC company Callio Therapeutics Inc by licencing Hummingbird Bioscience’s TopDDRive dual payload ADC technology and co-leading a US$187m … more ➔
Brainomix Ltd.
Evonik
Adobe stock photos - DARIKA
Polish Ministry of Agriculture - MRiRW
SpliceBio
FSA UK
asobe stock photos - catalin 
Adobe stock - maurice norbert 
Roche AG
Hummingbird Bioscience